Can your genes predict prostate cancer drug success?

NCT ID NCT03833921

First seen Jan 11, 2026 · Last updated May 04, 2026 · Updated 17 times

Summary

This study looks at men with prostate cancer that has spread, who are receiving standard treatment with abiraterone and prednisone. Researchers want to see if a person's race, ethnicity, and genetic makeup affect how well the treatment works. About 130 men will be followed for up to 10 years to track their PSA levels and genetic markers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ben Taub General Hospital

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Michael E. DeBakey Veterans Affairs Medical Center

    ACTIVE_NOT_RECRUITING

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.